UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Annals of oncology, 2015-08, Vol.26 (8), p.1547-1573

2015

Volltextzugriff (PDF)

ESMO-Magnitude of Clinical Benefit Scale version 1.1

Annals of oncology, 2017-10, Vol.28 (10), p.2340-2366

2017

Volltextzugriff (PDF)

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Annals of oncology, 2020-12, Vol.31 (12), p.1734-1745

2020

Volltextzugriff (PDF)

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Annals of oncology, 2019-12, Vol.30 (12), p.1902-1913

2019

Volltextzugriff (PDF)

Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Annals of oncology, 2022-05, Vol.33 (5), p.511-521

2022

Volltextzugriff (PDF)

Gender medicine and oncology: report and consensus of an ESMO workshop

Annals of oncology, 2019-12, Vol.30 (12), p.1914-1924

2019

Volltextzugriff (PDF)

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

The Lancet (British edition), 2015-10, Vol.386 (10001), p.1353-1361

2015

Volltextzugriff (PDF)

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Lung cancer (Amsterdam, Netherlands), 2019-07, Vol.133, p.83-87

2019

Volltextzugriff (PDF)

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis

Annals of oncology, 2024-10, Vol.35 (10), p.860-872

2024

Volltextzugriff (PDF)

Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis

European journal of cancer (1990), 2021-01, Vol.142, p.63-82

2021

Volltextzugriff (PDF)

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Annals of oncology, 2023-12, Vol.34 (12), p.1097-1112

2023

Volltextzugriff (PDF)

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Annals of oncology, 2019-02, Vol.30 (2), p.161-165

2019

Volltextzugriff (PDF)

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Annals of oncology, 2017-11, Vol.28 (11), p.2901-2905

2017

Volltextzugriff (PDF)

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0

Annals of oncology, 2023-09, Vol.34 (9), p.734-771

2023

Volltextzugriff (PDF)

Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period

The Journal of infection, 2022-05, Vol.84 (5), p.722-746

2022

Volltextzugriff (PDF)

YI02.03 Statistical Pitfalls in Clinical Trial Design

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S1116-S1117

Dafni, U.

2019

Volltextzugriff (PDF)

Fifteen-year trends in metastatic breast cancer survival in Greece

Breast cancer research and treatment, 2010-02, Vol.119 (3), p.621-631

2010

Volltextzugriff (PDF)

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Annals of oncology, 2013-04, Vol.24 (4), p.1011-1017

2013

Volltextzugriff (PDF)

Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug

Lung cancer (Amsterdam, Netherlands), 2020-08, Vol.146, p.217-223

2020

Volltextzugriff (PDF)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

ESMO open, 2021-06, Vol.6 (3), p.100117-100117, Article 100117

2021

Volltextzugriff (PDF)

Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”

Annals of oncology, 2017-11, Vol.28 (11), p.2901-2905

2017

Volltextzugriff (PDF)

Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients

Annals of oncology, 2018-12, Vol.29, p.x40-x40

2018

Volltextzugriff (PDF)

Second line treatment for EGFR wild-type advanced NSCLC: The Jury is Still Out

Lung cancer (Amsterdam, Netherlands), 2014-06, Vol.84 (3), p.314-315

2014

Volltextzugriff (PDF)

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial

Annals of oncology, 2018-10, Vol.29, p.viii498-viii498

2018

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(194)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(104)
Life Sciences & Biomedicine
(99)
Humans
(92)
Female
(69)
Biological And Medical Sciences
(63)
Medical Sciences
(60)
Oncology
(59)
Middle Aged
(55)
Adult
(50)
Male
(47)
Aged
(41)
Tumors
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Breast Cancer
(18)
Pharmacology. Drug Treatments
(18)
Aged, 80 And Over
(16)
Chemotherapy
(16)
Treatment Outcome
(16)
Breast Neoplasms - Drug Therapy
(15)
Gynecology. Andrology. Obstetrics
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

ESMO-Magnitude of Clinical Benefit Scale version 1.1

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Gender medicine and oncology: report and consensus of an ESMO workshop

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis

Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0

Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period

YI02.03 Statistical Pitfalls in Clinical Trial Design

Fifteen-year trends in metastatic breast cancer survival in Greece

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”

Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients

Second line treatment for EGFR wild-type advanced NSCLC: The Jury is Still Out

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial

Suchergebnisse filtern